Vision loss with pembrolizumab treatment: A report of two cases

Abstract

Background

Vision loss and other ocular toxicities are rare, but detrimental, side effects of immune checkpoint inhibitors. Herein, we report two patients who developed vision loss while on pembrolizumab treatment.

Cases presentation

Case 1 – A 58-year-old man was started on pembrolizumab for advanced melanoma. He was tolerating the treatment well. After receiving 14 cycles of pembrolizumab, he developed acute bilateral vision loss and occipital headaches. An emergent ophthalmologic evaluation revealed bilateral shallow choroidal effusion with bilateral focal exudative retinal detachment. After excluding other possible etiologies, inflammatory process secondary to pembrolizumab was suspected. Pembrolizumab was stopped, and the patient was started on a course of systemic and topical steroids. His vision improved within days and he recovered completely within two months. Calculated Naranjo Nomogram score was 7 indicating a “probable” correlation; Case 2 – A 57-year-old man with stage IIIC melanoma was started on adjuvant pembrolizumab. After a few weeks of treatments, he reported minor bilateral vision changes that progressively worsened over a period of six months. An ophthalmologic evaluation revealed bilateral posterior uveitis with right optic disc edema. Pembrolizumab-related inflammatory changes were suspected, and he was started on systemic and topical steroids. His symptoms improved within a few weeks and steroids were tapered. He was re-challenged with pembrolizumab and his symptoms quickly re-occurred. Pembrolizumab was stopped indefinitely and the patient again treated with systemic and topical steroids. His symptoms resolved and his vision returned to baseline within two months. The Naranjo Nomogram score was 9 indicating a “definite” correlation.

Conclusions

Vision loss is a serious complication that may occur at any point during treatment with PD-1 inhibitors. Vision loss is very distressing to the patients and their families. It is prudent for practitioners to recognize early vision abnormalities in patients receiving PD-1 antagonists to prevent permanent vision loss.

Keywords

Pembrolizumab vision loss PD-1 ophthalmic uveitis

Get full access to this article

View all access options for this article.

References

Gangadhar

Salama

. Clinical applications of PD-1-based therapy: a focus on pembrolizumab (MK-3475) in the management of melanoma and other tumor types. Onco Targets Ther 2015; 8: 929–937.

FDA, FDA medication guide. 2017.

Antoun

Titah

Cochereau

. Ocular and orbital side-effects of checkpoint inhibitors: a review article. Curr Opin Oncol 2016; 28: 288–294.

Naranjo

et al.

A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981; 30: 239–245.

Aaberg

Jr . Pembrolizumab administration associated with posterior uveitis. Retin Cases Brief Rep 2017; 11: 348–351.

Abu Samra

et al.

A case of bilateral uveitis and papillitis in a patient treated with pembrolizumab. Eur J Ophthalmol 2016; 26: e46–e48.

Basilious

Lloyd

. Posterior subcapsular cataracts and hypotony secondary to severe pembrolizumab induced uveitis: case report. Can J Ophthalmol 2016; 51: e4–6.

Diem

et al.

Pembrolizumab-triggered uveitis: an additional surrogate marker for responders in melanoma immunotherapy?

J Immunother 2016; 39: 379–382.

Hanna

. A rare case of pembrolizumab-induced uveitis in a patient with metastatic melanoma. Pharmacotherapy 2016; 36: e183–e188.

10.

Karlin

Gentzler

Golen

. Bilateral anterior uveitis associated with nivolumab therapy. Ocul Immunol Inflamm 2016; 26: 283–285.

11.

Baughman

et al.

Bilateral uveitis and keratitis following nivolumab treatment for metastatic melanoma. Med Case Rep (Wilmington) 2017; 3: 8–8.

12.

Theillac

et al.

Bilateral uveitis and macular edema induced by Nivolumab: a case report. BMC Ophthalmol 2017; 17: 227–227.

13.

Arai

et al.

Case of acute anterior uveitis and Vogt-Koyanagi-Harada syndrome-like eruptions induced by nivolumab in a melanoma patient. J Dermatol 2017; 44: 975–976.

14.

Wang

Lam

Chen

. Recurrent grade 4 panuveitis with serous retinal detachment related to nivolumab treatment in a patient with metastatic renal cell carcinoma. Cancer Immunol Immunother 2019; 68: 85–95.

15.

Kartal

Atas

. Bilateral optic neuritis secondary to nivolumab therapy: a case report. Medicina (Kaunas) 2018; 54: 82–82.

16.

Reddy M, et al. Immune Retinopathy Associated with Nivolumab Administration for Metastatic Non-Small Cell Lung Cancer. Retinal Cases & Brief Reports 2017; 1–7.

17.

Tsui

et al.

Combination ipilimumab and nivolumab for metastatic melanoma associated with ciliochoroidal effusion and exudative retinal detachment. JAMA Ophthalmol 2017; 135: 1455–1457.

18.

Park

ESY

et al.

A case of Graves' ophthalmopathy associated with pembrolizumab (Keytruda) therapy. J AAPOS 2018; 22: 310–312.

19.

Alnabulsi

Hussain

DeAngelis

. Complete ophthalmoplegia in Ipilmumab and Nivolumab combination treatment for metastatic melanoma. Orbit 2018; 37: 381–384.

20.

Acaba-Berrocal

et al.

Birdshot-like chorioretinopathy associated with pembrolizumab treatment. JAMA Ophthalmol 2018; 136: 1205–1207.

21.

Bricout

et al.

Vogt-Koyanagi-Harada-like syndrome complicating pembrolizumab treatment for metastatic melanoma. J Immunother 2017; 40: 77–82.

22.

Nguyen

et al.

Cyclosporine for dry eye associated with nivolumab: a case progressing to corneal perforation. Cornea 2016; 35: 399–401.

23.

Kim, J.M., et al., Ophthalmic Immune-Related Adverse Events of Immunotherapy: A Single-Site Case Series. Ophthalmology 2019.

24.

Le Fournis

et al.

Corneal graft rejection in a patient treated with nivolumab for primary lung cancer. Lung Cancer 2016; 102: 28–29.

25.

Puzanov

et al.

Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group. J Immunother Cancer 2017; 5: 95–95.

26.

Management of Immunotherapy-Related Toxicities/Immune Checkpoint-Inhibitor Toxicities. National Comprehensive Cancer Network, 2018. Version 1.2019.

27.

Wilson

et al.

Acute visual loss after ipilimumab treatment for metastatic melanoma. J Immunother Cancer 2016; 4: 66–66.

28.

Berson

Lessell

. Paraneoplastic night blindness with malignant melanoma. Am J Ophthalmol 1988; 106: 307–311.

29.

Keltner

Thirkill

Yip

. Clinical and immunologic characteristics of melanoma-associated retinopathy syndrome: eleven new cases and a review of 51 previously published cases. J Neuroophthalmol 2001; 21: 173–187.

30.

Robert

et al.

Chorioretinal lesions in a case of melanoma-associated retinopathy treated with pembrolizumab. JAMA Ophthalmol 2016; 134: 1184–1188.